Occam Recruits Chief Commercial Officer at Geron
In September 2024, Occam Global recruited Jim Ziegler as Chief Commercial Officer of Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical oncology company.
In this role, Ziegler will spearhead the company’s global commercial strategy and operations and drive the growth of RYTELO™, Geron’s first marketed product.
Ziegler has over 25 years of commercial experience in the biopharmaceutical industry, spanning strategic and operational leadership roles in large and smaller organizations.
Ziegler joins Geron from Iovance Biotherapeutics (Nasdaq:IOVA), where he served as Executive Vice President of Commercial, with global responsibilities for the company’s novel autologous cell therapy program and led the U.S. commercial launch of Amtagvi™. Previously, he served in numerous commercial leadership roles at Gilead, Biogen, Amgen, and Pfizer.
Prior to the biopharmaceutical industry, Jim honorably served his country as an Armor Officer in the U.S. Army. Ziegler received a B.S. from the United States Military Academy at West Point and an M.B.A. from the University of Chicago.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.